Electronic components manufacturer CTS Corporation (NYSE: CTS) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 7% year on year to $144.8 million. The company’s full-year revenue guidance of $575 million at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $0.74 per share was 21.3% above analysts’ consensus estimates.
Is now the time to buy CTS? Find out in our full research report (it’s free for active Edge members).
CTS (CTS) Q2 CY2026 Highlights:
- Revenue: $144.8 million vs analyst estimates of $143.4 million (7% year-on-year growth, 0.9% beat)
- Adjusted EPS: $0.74 vs analyst estimates of $0.61 (21.3% beat)
- Adjusted EBITDA: $36.8 million vs analyst estimates of $31.46 million (25.4% margin, 17% beat)
- The company slightly lifted its revenue guidance for the full year to $575 million at the midpoint from $570 million
- Management raised its full-year Adjusted EPS guidance to $2.63 at the midpoint, a 9.4% increase
- Operating Margin: 18.6%, up from 17% in the same quarter last year
- Market Capitalization: $1.85 billion
StockStory’s Take
CTS delivered a positive second quarter, as evidenced by the strong market reaction following its results. Management credited robust growth in its diversified end markets—including medical, industrial, and aerospace/defense—as the primary drivers of financial performance. CEO Prateek Trivedi emphasized that “robust growth across our diversified end markets drove strong financial results and improved the quality of our earnings despite modest declines in transportation.” The company also noted operational improvements and a more profitable sales mix, while acknowledging one-time items that benefited earnings per share.
Looking ahead, CTS’s updated guidance is underpinned by continued momentum in its medical and industrial businesses, a recovering aerospace/defense segment, and a measured outlook for transportation. Management highlighted ongoing investments in capacity for medical applications and strong backlogs in aerospace/defense as contributors to the outlook, while cautioning that global light vehicle production remains uncertain due to tariffs and geopolitical factors. CFO Ashish Agrawal stated, “Our guidance strikes the right balance between resilience and growth of our diversified end markets, and a cautious stance on the light vehicle production trends.”
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to strong demand in diversified end markets and operational execution, while also highlighting the impact of end market mix and select one-time items.
-
Diversified End Markets Surge: The medical, industrial, and aerospace/defense segments collectively drove a 15% year-over-year increase in diversified revenue, now representing 59% of total sales. Growth in these areas offset declines in transportation, with medical sales supported by new product launches and expanded capacity.
-
Medical Market Expansion: CTS saw a 45% year-over-year jump in medical revenue, fueled by broad demand for sensing and actuation technologies in advanced diagnostics and therapeutics. Management highlighted engagement with leading equipment makers and a strong pipeline, positioning the company for future platform launches.
-
Industrial Momentum Continues: Industrial sales increased 16% year-over-year, with growth attributed to demand for automation, energy efficiency, and digitalization. New design wins in temperature sensing and EMI filters expanded CTS’s footprint in infrastructure and OEM applications.
-
Aerospace/Defense Recovery Expected: Although aerospace and defense sales declined 15% from the prior year due to funding timing, management cited a growing backlog and improving government funding flows. Participation in next-generation defense programs, including autonomous drones and secure communications, is expected to boost future results.
-
Transportation Mixed, but New Wins: Transportation revenue declined 2%, but CTS secured $163 million in new business awards, including a record sensor contract with a North American OEM and a new electric vehicle customer. Management stressed the importance of powertrain-agnostic solutions and noted modest growth expectations for commercial vehicles amid flat global production forecasts.
Drivers of Future Performance
CTS’s outlook is shaped by ongoing strength in diversified markets and persistent uncertainty in transportation, influenced by tariffs and shifting demand.
-
Medical and Industrial Growth: Management expects continued expansion in medical, driven by investments in capacity and a robust pipeline in diagnostics and therapeutics. Industrial demand is projected to remain healthy, supported by automation and energy efficiency trends that expand the addressable market.
-
Aerospace/Defense Recovery: The company anticipates stronger performance in aerospace and defense in the second half of the year, with a growing backlog and increased government funding for key programs. Participation in modern warfare platforms and advanced sensing applications is expected to underpin growth.
-
Transportation Headwinds: CTS is cautious about transportation demand, especially in light vehicles, due to ongoing tariff, geopolitical, and consumer uncertainties. While commercial vehicles may see modest improvement—partly due to pre-buy activity ahead of emissions regulations—management remains vigilant about cost pressures and program launches potentially impacting margins.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) whether medical and industrial segments sustain their growth trajectory through continued new wins and capacity ramp-up; (2) the pace of aerospace and defense backlog conversion as government funding flows into key programs; and (3) the impact of tariff and cost pressures on transportation margins, particularly as new product launches roll out. Execution on pricing strategies and supply chain negotiations will also be key variables to watch.
CTS currently trades at $64.82, up from $60.41 just before the earnings. Is there an opportunity in the stock? Find out in our full research report (it’s free).
High Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
